Ocular Therapeutix to Present SOL-1 Phase 3 AXPAXLI Data on April 11 and 15
Ocular Therapeutix will present SOL-1 Phase 3 trial data on AXPAXLI for wet AMD at the Vit-Buckle Society Meeting in Las Vegas on April 11 and at the Congreso Nacional de Oftalmologia in Buenos Aires April 15–17. Drs. Pravin Dugel, Jeffrey Heier and Peter Kaiser will detail neovascular AMD and diabetic retinal disease outcomes.
1. Upcoming Conference Presentations
Ocular Therapeutix will showcase additional SOL-1 Phase 3 superiority trial analyses at two scientific meetings in April 2026. The Vit-Buckle Society Meeting in Las Vegas on April 11 will feature a symposium on neovascular AMD led by Drs. Jeffrey Heier, Peter Kaiser and Andrew Moshfeghi. From April 15–17 at the Congreso Nacional de Oftalmologia in Buenos Aires, CEO Dr. Pravin Dugel will deliver three sessions covering TKIs, diabetic retinal disease and wet AMD.
2. AXPAXLI Phase 3 Program
AXPAXLI (OTX-TKI) is an investigational axitinib intravitreal hydrogel developed on the ELUTYX™ bioresorbable platform, currently in Phase 3 for wet AMD and non-proliferative diabetic retinopathy. These conference presentations will provide deeper insights into dosing efficacy, anatomical outcomes and safety profiles observed in the SOL-1 trial.
3. Investor Implications
Detailed SOL-1 data releases can serve as catalysts by refining efficacy expectations and influencing investor sentiment ahead of potential regulatory submissions. Positive outcomes in neovascular AMD and diabetic retinal disease cohorts may accelerate valuation re-ratings as Ocular Therapeutix advances toward late-stage milestones.